Published in Women's Health Weekly, March 25th, 2010
"Specifically, we examined the toxicity to hosts and specificity of targeting ovarian tumors using a Wv ovarian tumor model. We first tested recombinant VSV for oncolytic activity in a panel Of human ovarian epithelial cancer, immortalized, and primary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly